MSFrontier

TERI-PRO

A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
CompletedPhase 4Relapsing MS2013-001439-34

What was tested

Treatment tested

What it measured

Main measures

  • Assessment at 48 weeks (W48/EOT) of global satisfaction with teriflunomide treatment, measured by the Treatment Satisfaction Questionnaire for Medicine (TSQM) version 1.4 score

    Quality of life (reported by participants)

Other measures (1)

  • 1 - Change in TSQM version 1.4 from baseline to W4 and to W48/EOT of teriflunomide treatment in patients switching from another DMT

Loading reviews and guidelines…

Related trials

  • TWINS

    Phase 3 · Not yet recruiting

    Still running

  • ENSURE-2

    Phase 3 · Moved to EU CTIS registry

  • AIOLOS

    Recruiting

    Still running

  • ENSURE-1

    Phase 3 · Completed

  • FENhance 2

    Phase 3 · Running, not recruiting

    Still running

  • FENhance

    Phase 3 · Running, not recruiting

    Still running

History

  1. In scope changed from true to false

  1. Started

    Sept 2013

Assembled by software from public sources and not checked by people. Each record links to its source. Report an error